Cargando…

Revised algorithm for heparin anticoagulation during continuous renal replacement therapy

Detalles Bibliográficos
Autores principales:	Dickie, Helen, Tovey, Linda, Berry, William, Ostermann, Marlies
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624355/ https://www.ncbi.nlm.nih.gov/pubmed/26502904 http://dx.doi.org/10.1186/s13054-015-1099-y

Ejemplares similares

Heparin algorithm for anticoagulation during continuous renal replacement therapy
por: Ostermann, Marlies, et al.
Publicado: (2010)

Management of sodium disorders during continuous haemofiltration
por: Ostermann, Marlies, et al.
Publicado: (2010)

Clearance of micronutrients during continuous renal replacement therapy
por: Lumlertgul, Nuttha, et al.
Publicado: (2020)

Association between type of anticoagulation and blood transfusion requirements during renal replacement therapy in the ICU
por: Iyer, A, et al.
Publicado: (2011)

Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care
por: Doidge, James C., et al.
Publicado: (2023)

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy
por: Vargas Hein, O, et al.
Publicado: (2000)

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2011)

The effect of regional citrate anti-coagulation on the coagulation system in critically ill patients receiving continuous renal replacement therapy for acute kidney injury - an observational cohort study
por: Fisher, Richard, et al.
Publicado: (2017)

Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children
por: Raymakers-Janssen, Paulien A. M. A., et al.
Publicado: (2017)

Addition of prostacyclin to heparin does not prolong circuit life during continuous haemofiltration
por: Ostermann, M, et al.
Publicado: (2010)

Anticoagulation during continuous renal replacement therapy with lepirudin in patients with heparin-induced thrombocytopenia
por: Schroeder, T, et al.
Publicado: (2005)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Anticoagulation in COVID-19 patients requiring continuous renal replacement therapy
por: Attallah, Nizar, et al.
Publicado: (2021)

Successful management of severe hyponatraemia during continuous renal replacement therapy
por: Vassallo, Diana, et al.
Publicado: (2012)

Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2012)

Periprocedural anticoagulation in transcatheter aortic valve replacement: Heparin vs bivalirudin
por: Minhas, Abdul Mannan Khan, et al.
Publicado: (2017)

Optimizing citrate dose for regional anticoagulation in continuous renal replacement therapy: measuring citrate concentrations instead of ionized calcium?
por: Honore, Patrick M., et al.
Publicado: (2015)

Citrate anticoagulation for continuous renal replacement therapy in small children
por: Soltysiak, Jolanta, et al.
Publicado: (2013)

Regional citrate anticoagulation for continuous renal replacement therapy in newborns
por: Huang, Haixia, et al.
Publicado: (2023)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study
por: Fisher, Richard, et al.
Publicado: (2022)

Regional Citrate Anticoagulation or Heparin Anticoagulation for Renal Replacement Therapy in Patients With Liver Failure: A Systematic Review and Meta-Analysis
por: Qi, Wenqian, et al.
Publicado: (2023)

Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?
por: Anton, Florin Ioan, et al.
Publicado: (2020)

An Antithrombin-Heparin Complex Increases the Anticoagulant Activity of Fibrin Clots
por: Smith, Lesley J., et al.
Publicado: (2008)

Adsorption and caspofungin dosing during continuous renal replacement therapy
por: Honore, Patrick M., et al.
Publicado: (2019)

Measuring biomarkers of acute kidney injury during renal replacement therapy: wisdom or folly?
por: Ostermann, Marlies, et al.
Publicado: (2014)

Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers
por: Kindgen-Milles, Detlef, et al.
Publicado: (2015)

Renal failure in the intensive care unit: acute kidney injury compared to end-stage renal failure
por: Ostermann, Marlies, et al.
Publicado: (2008)

Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial
por: Stucker, Fabien, et al.
Publicado: (2015)

The furosemide stress test to predict renal function after continuous renal replacement therapy
por: van der Voort, Peter HJ, et al.
Publicado: (2014)

Fluid removal associates with better outcomes in critically ill patients receiving continuous renal replacement therapy: a cohort study
por: Hall, Anna, et al.
Publicado: (2020)

Distinction between induction and maintenance dosing in continuous renal replacement therapy
por: MacLaren, Graeme
Publicado: (2011)

‘Biomarking’ infection during continuous renal replacement therapy: still relevant?
por: Honore, Patrick M, et al.
Publicado: (2015)

Endocan is a reliable biomarker during continuous renal replacement therapy
por: Hureau, Maxence, et al.
Publicado: (2019)

Correlation between parameters at initiation of renal replacement therapy and outcome in patients with acute kidney injury
por: Ostermann, Marlies, et al.
Publicado: (2009)

Anticoagulation during Renal Replacement Therapy
por: Singh, Simran
Publicado: (2020)

Citrate Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients: Success and Limits
por: Mariano, Filippo, et al.
Publicado: (2011)

Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure
por: Rodriguez, Keila, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gb789angbhlot25uq7r9j1pihk